novo nordisk lawsuits against compounding pharmacies semaglutide 2023 2024 2025 Pharma giants defend high-stakes lawsuit over weight loss drugs FDA free to pursue semaglutide

It included a box warning regarding the risk of thyroid C-cell tumors with contraindications for patients with: A personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 Serious hypersensitivity to tirzepatide or any Zepbound excipients Monitoring is encouraged to look for symptoms of thyroid tumors, such as a lump in the neck, unexplained hoarseness, trouble swallowing, and shortness of breath

Physical therapy provides the mechanical loading and strengthening that promotes disc health, while peptides support the cellular repair processes

Tirzepatide was FDA approved across multiple global markets beginning in 2022

The appetite suppression profile is similar because both compounds activate GLP-1 receptors, but many users report that retatrutide appetite suppression feels qualitatively different